Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? (Cost-Less)
|ClinicalTrials.gov Identifier: NCT00804960|
Recruitment Status : Withdrawn (lack of recruitment at this site)
First Posted : December 9, 2008
Last Update Posted : June 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: Letrozole Drug: Std IVF Protocol||Phase 4|
- To determine whether addition of letrozole to gonadotropins would reduce the amount of gonadotropins used in an IVF-ET cycle, thereby reducing the cost.
- To determine whether letrozole improves IVF-ET success compared to standard ovarian stimulation protocols.
Null Hypothesis: Use of Letrozole for ovulation induction in IVF is not less expensive than the standard therapy by a clinically relevant amount.
Alternative Hypothesis: Use of Letrozole for ovulation induction in IVF is better than the standard therapy by a clinically relevant amount.
Infertile women <40 years of age with age-appropriate ovarian reserve (as determined by day2/3 E2, FSH, and AMH) will be randomized between two protocols: one with letrozole and one with standard ovulation induction.
In both groups, serum FSH will be measured each time a sample is obtained for estradiol. Sera will be frozen for further batch assay.
Number of embryos to be transferred will be decided following the ASRM guidelines. The day of embryo transfer (D-3 vs D-5) will be based on the number and quality of embryos as per established clinical criteria.
A review of 1473 cycles of patients less than 40 years old over the last 6 years (2002 - 2008) revealed average cost per cycle to be $3,152 +/- 1685(SD).
For the purpose of this power analysis we consider a 20% decrease in medication cost to be clinically significant. Thus a decrease from $ 3152.83 to $ 2522.26 will be considered clinically significant (20% decrease). For an alpha of 0.05 and a power of 80% for a two tailed test 113 patients will need to complete each arm.
Allowing for 10% drop-out we will attempt to randomize 125 patients to each arm of the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Controlled Ovarian Stimulation With Letrozole Supplementation|
|Study Start Date :||September 2008|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||April 2010|
1) Letrozole/ Recombinant FSH
1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
Other Name: Femara
Active Comparator: Standard IVF
luteal phase GnRHa suppression/gonadotropin
Drug: Std IVF Protocol
2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
Other Name: Ovulation induction with Human Menopausal gonoadotropins
- Cost of Treatment [ Time Frame: 4 weeks ]
- Pregnancy and implantation rates [ Time Frame: 4 weeks ]
- Incidence of Ovarian Hyper stimulation Syndrome [ Time Frame: 4 weeks ]
- Multiple Birth Rate [ Time Frame: 10 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00804960
|United States, New York|
|Center for Human Reproduction|
|New York, New York, United States, 10021|
|Study Director:||David Barad, MD. MS||CHR|
|Principal Investigator:||Kutluk Oktay, MD||CHR/ New York Medical College|